Long-term response to daratumumab in a patient with advanced immunoglobulin light-chain (AL) amyloidosis with organ damage

Ann Hematol. 2019 Apr;98(4):1047-1048. doi: 10.1007/s00277-018-3566-4. Epub 2018 Nov 28.

Authors

Martina Canichella¹, Alessandra Serrao¹, Giorgia Annechini¹, Gianna Maria D'Elia¹, Maria Lucia De Luca¹, Alessandro Pulsoni²

Affiliations

¹ Department of Cellular Biotechnologies and Hematology, Sapienza University of Rome, Via Benevento 6, 00161, Rome, Italy.
² Department of Cellular Biotechnologies and Hematology, Sapienza University of Rome, Via Benevento 6, 00161, Rome, Italy. pulsoni@bce.uniroma1.it.

PMID: 30488327
DOI: 10.1007/s00277-018-3566-4

No abstract available

Publication types

Case Reports
Letter

MeSH terms

Aged
Antibodies, Monoclonal / administration & dosage*
Female
Humans
Immunoglobulin Light-chain Amyloidosis / blood
Immunoglobulin Light-chain Amyloidosis / drug therapy*
Time Factors

Substances

Antibodies, Monoclonal
daratumumab